About

Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.

Articles

Statins: Practical Considerations – A Review

Citation:

European Cardiology Review 2014;9(2):71–5

The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease

Citation:

European Cardiology Review 2014;9(1):10–5

The Emerging Role of PCSK9 Inhibitors in Preventive Cardiology

Citation:

European Cardiology Review 2014;9(2):65–70

Current Treatment of Familial Hypercholesterolaemia

Citation:

European Cardiology Review 2014;9(2):76–81